Thus, under imatinib suppression, GIST cells may avoid apoptosis by exiting the cell cycle and expressing genes associated with a differen- tiated phenotype. Whether these cells proliferate again when a TKI is discontinued, or whether GIST stem cells are the source of renewed growth, has not ...
In cases of recurrent or metastatic DFSP, treatment options may be more limited, and the goal of treatment is typically to control the tumor and relieve symptoms. In these cases, targeted therapy with imatinib mesylate or other drugs may be used, along with radiation therapy or surgery as appr...
A new prognostic classification of GIST has been proposed: it acknowledges the existence of truly benign GISTs and is adapted to the primary site of the lesion in order to underline the usually better prognosis of gastric GISTs. The search for mutations of KIT et PDGRA must be done in ...
Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.Ann Surg. 2005;242:684–92. Article...
B. After 4 cycles of chemotherapy with Tarceva there is significant decrease in the size of the metastatic mass in the right breast. Full size image Table 1 Tumor response criteria — WHO, RECIST 1.0 and RECIST 1.1 and classification of tumor assessment Full size table Figure 3 68 year ...
Classification of neuroendocrine neoplasms of the digestive system. In WHO Classification of Tumours: Digestive System Tumours, 5th ed.; WHO Classification of Tumours Editorial Board, Ed.; International Agency for Research on Cancer: Lyon, France, 2019; p. 16. [Google Scholar] Dasari, A.; Mehta...